ProAgio for advanced pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called ProAgio combined with standard chemotherapy for people with stage IV pancreatic cancer. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage IV pancreatic cancer that has spread.
- You have not had gemcitabine and nab-paclitaxel before.
- You are healthy enough to undergo a biopsy of your tumor.
- Your cancer can be measured on scans (RECIST criteria).
- You are in good physical condition (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MRG003 combined with gemcitabine for people with advanced pancreatic cancer that has stopped responding to or cannot tolerate initial treatment. It aims to see if the combination can shrink tumors or slow the disease.
This trial tests a new drug called ProAgio combined with the chemotherapy gemcitabine for people with triple-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two chemotherapy drugs (AG) plus an immunotherapy (cadonilimab) and a short course of radiation for people with locally advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this approach helps shrink or control the tumor.
This trial tests a drug combination (AG and nimotuzumab) followed by a procedure called irreversible electroporation (IRE) to treat locally advanced pancreatic cancer that hasn't spread. It aims to see if this approach can help patients whose cancer can't be removed by surgery.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
This trial tests a new combination treatment (PRaG therapy) for patients with locally advanced pancreatic cancer that has not spread. It aims to help shrink the tumor so it can be removed surgically, and it is for patients who have not had prior radiation, chemotherapy, or immunotherapy.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.